



2023 Community Oncology Forum

Saturday, April 8th, 2023 - 9:00 am – 2:30 pm

The Mirage
3400 S Las Vegas Blvd.
Las Vegas, NV 89109

Chinese American Hematologist & Oncologist Network (CAHON)

美国华裔血液及肿瘤专家学会

Organizing Committee

Bo Zhao, MD

Virginia Oncology Associates

Yi Feng, MD, PhD

Tennessee Cancer Specialists

Shuang Fu, MD, PhD

Jackson Hematology & Oncology Associates

Bo Wang, MD

Willamette Valley Cancer Institute AND Research Center

Mary Li, MD, PhD

Florida Cancer Specialists

Joyce Huang, MD, PhD

Cancer Care Associates of York

Lulu Zhang, MD, MPH

Pacific Cancer Care

Wenqing Zhang, MD, PhD

Florida Cancer Specialists

David Z. Chang, MD, PhD, FACP

Virginia Oncology Associates

www.cahon.org

2023 Corporate Partners



2023 Annual Supporters



Silver Sponsor



Exhibitors





SCAN TO DISCOVER MORE

CABOMETRYXhcp.com

CONTENTS

Event Sponsors	page 1
About CAHON	page 3
Upcoming CAHON Events	page 5
Meeting Agenda	page 6-7
About Our Speakers	page 8



ABOUT CAHON

Founded by Chinese American Hematologists and Oncologists in 2005, the primary missions of CAHON are to foster communications amongst Chinese American medical professionals for the delivery of high-quality health care to patients with neoplastic and hematological diseases, and to promote medical information exchange between the United States and China in the field of hematology and oncology. CAHON strives to serve as a bridge among its members and between Chinese and American Hematology-Oncology communities for medical and educational exchange.

THE STORY BEHIND THE LOGO

CAHON'S logo was designed by Drs. Weijing Sun, Ke Liu, and Jeffrey Ye, under the supervision of the CAHON Board. The design has the following elements and takes the following considerations:

- The overall shape represents the globe.
- The blue, white, red and yellow represent the colors of two nations' flags. China and the US.
- The yellow and red stripes above the blue, represent bridges. One of CAHON's key missions is to serve as a bridge between Chinese American Hematology-Oncology communities for medical and educational exchange.
- The white space is in the shape of a heart. The hearts of our members continue to drive our mission to provide high quality patient care to everyone.

CAHON MEMBERSHIP

Apply to become a CAHON Member at cahon.org

Value of a CAHON Membership

By joining CAHON you will have access to:

- A growing network of Chinese American professionals working in your field;
- A private WeChat group where you can submit clinical questions to respected colleagues who are knowledgeable in specific areas of hematology and oncology;
- Reduced or waived registration fees for all CAHON events and meetings along with priority hotel reservations;
- Members-only section of the CAHON website featuring the member directory; and
- Travel award opportunities.

MEMBERSHIP CATEGORIES

Regular/Active Membership

Associate Membership

Allied Membership

Visit cahon.org/membership for more information on membership.





SARCLISA[®]

(isatuximab-irfc)

Injection for IV use | 500 mg/25 mL, 100 mg/5 mL

See the latest data for **SARCLISA + Kd**

Explore the full results of the
IKEMA phase 3 trial at
sarclisahcp.com



Kd=Kyprolis (carfilzomib) and dexamethasone

Save the Dates!

SUMMER SYMPOSIUM AND RECEPTION

June 3, 2023
The Metropolitan
Chicago, IL

Held in conjunction with ASCO, the Summer Symposium will offer expert perspectives and practical insights on current advancements in a variety of cancer treatments, as well as foster collaboration and provide a forum for interaction and collaboration between hematologists and oncologists.

10th ANNUAL NEW YORK ONCOLOGY FORUM (NYOF)

October 7-8, 2023
Sheraton La Guardia East
Flushing, NY

The CAHON annual New York Oncology Forum (NYOF) is a one and a half day educational program that includes presentations on new developments and updates from the latest ASH, ASCO and SITC meetings including novel agents for Hematology and Oncology. 2023 will mark the 10th anniversary for this annual event and it draws more than 100 clinicians, researchers, medical students, clinical fellows as well as laboratory and health care related scientists working in the hematology and oncology.

WINTER SYMPOSIUM & RECEPTION

December 9, 2023
University Club Atop Symphony Tower
San Diego, CA

Held in conjunction with ASH, the Winter Symposium will offer expert perspectives and practical insights on current advancements in a variety of cancer treatments, as well as foster collaboration and provide a forum for interaction and collaboration between hematologists and oncologists.



Meeting Agenda

7:00 am	On-site Registration, Exhibitors Visitation
7:30 – 8:30 am	Promotional Talk – Sponsored by Sanofi An Anti-CD38 Combination for the Treatment of Multiple Myeloma as Early as First Relapse Speaker: Bo Wang, MD – <i>Willamette Valley Cancer Institute and Research Center</i>
8:30 – 9:00 am	Break & Visit the Exhibitors
9:00 – 9:05 am	Opening Remarks Bo Zhao, MD – <i>CAHON President, Virginia Oncology Associates</i>
9:05 – 9:25 am	Lecture 1: Diagnosis and management of primary CNS lymphomas and ocular lymphomas Speaker: Jay-Jiguang Zhu, MD PhD – <i>McGovern Medical School at UTHealth</i> Moderator: Fei Gu, MD – <i>Nexus Oncology</i> Jane Liu, MD – <i>Illinois Cancer Care</i>
9:25 – 9:45 am	Lecture 2: The Management of Acute Myeloid Leukemia Speaker: Onyee Chan, MD – <i>Moffitt Cancer Center</i> Moderator: Deng Zhang, MD, PhD – <i>Hematology Oncology of Indiana</i> Hongtao Liu, MD, PhD – <i>University of Chicago</i>
9:45 – 10:05 am	Lecture 3: GU Cancer Update Speaker: Jingsong Zhang, MD, PhD – <i>Moffitt Cancer Center</i> Moderator: Gary G. Tian, MD, PhD – <i>West Cancer Center</i> Zhentao Zhang, MD, PhD – <i>Parkview Cancer Institute</i>
10:05 – 10:10 am	Introduction of CAHON Corporate Partners and Annual Supporters (1 min each)
10:10 – 10:30 am	Break & Visit the Exhibitors
10:30 – 10:50 am	Lecture 4: Breast Cancer Update Speaker: Fengting Yan, MD, PhD – <i>Swedish Cancer Institute</i> Moderator: Faye Yin, MD – <i>RWJ University Hospital Somerset</i> Xuan Huang, MD, PhD – <i>Aspirus Health Cancer Care</i>
10:50 – 11:10 am	Lecture 5: GI Cancer Update Speaker: Eric Xueyu Chen, PhD, MD – <i>Princess Margaret Cancer Centre</i> Moderator: Zhaohui Jin, MD – <i>Mayo Clinic</i> Yue Zhang, MD, MPH – <i>Virginia Oncology Associates</i>

Meeting Agenda

- 11:10 – 11:35 am **Lung Cancer Case Discussion**
Moderator: Tianhong Li, MD, PhD – *UC Davis Cancer Center*
Case Presentation: Chen Zhang, MD – *Rush University Graduate College*
Panelists: Zhihong Julia Zhang, MD – *The Everett Clinic*
 Wei Bai, MD – *Mission Hope Cancer Center*
 Lei Deng, MD – *Roswell Park Comprehensive Cancer Center*
- 11:35 am – 12:00 pm **Lymphoma Case Discussion**
Moderator: Yucai Wang, MD, PhD – *Mayo Clinic*
Case Presentation: Zhengrui Xiao, MD – *Montefiore Medical Center*
Panelists: Delong Liu, MD, PhD – *New York Medical College*
 Hongtao Liu, MD, PhD – *University of Chicago*
- 12:00 – 1:00 pm **Promotional Talk – Sponsored by Exelixis**
A Combination Treatment for Patients with Advanced Renal Cell Carcinoma
Speaker: Sandy Liu, MD – *City of Hope Orange County*
- 1:00 – 1:45 pm **Lecture 6: Clinic Workflow**
Moderator: Yi Feng, MD, PhD – *Tennessee Cancer Specialists*
Panelists: Shuang Fu, MD, PhD – *Jackson Hematology & Oncology Associates*
 Mary Li, MD, PhD – *Florida Cancer Specialists*
 Ligeng Tian, MD, PhD – *Virginia Oncology Associates*
 Jianqing Lin, MD, MS, MA – *George Washington University Cancer Center*
 Qing Zhao, MD – *Banner MD Anderson*
 Chaoyang Li, MD – *Ohio Health*
 Tianyi Tang, MD, PhD – *John Muir Health Cancer Center*
 Grace Li, MD – *Kaiser Permanente*
 Haoran Li, MD, PhD – *Huntsman Cancer Institute*
 Min Yan, MD – *John Muir Health*
- 1:45 – 2:30 pm **Lecture 7: Physician Financial Planning**
Speaker: David Z. Chang, MD, PhD – *Virginia Oncology Associates*
Panelists: Peter Jiang, MD, PhD – *John B. Amos Cancer Center*
 Gary Lu, MD, PhD – *Texas Oncology*
 Hui Chen, MD, PhD – *Duke Cancer Institute*
- 2:30 – 2:35 pm **Concluding Remarks**
Ruirong Yuan, MD, PhD – *CAHON Board Chair*
- 2:35 – 4:00 pm **Social Networking**

Speakers



Jay-Jiguang Zhu (朱继光), MD, PHD, FAAN, neurologist and neuro-oncologist, is the Director of Neuro-oncology Service and professor at Neurosurgery Department and adjunct professor in Neurology Department in University of Texas Health Science Center in Houston (UTHealth) and Memorial Hermann at Texas Medical Center (TMC).

He is a board-certified neurologist by American Board of Psychiatry and Neurology and neuro-oncologist by United Council for Neurologic Subspecialties in Neuro-oncology subspecialty.

Dr. Zhu earned his medical degree (MDCM) from McGill University in Montreal, Quebec, Canada and completed his residency training in neurology at Tufts Medical Center, Tufts University, School of Medicine in Boston. He subsequently completed his fellowship in neuro-oncology at Massachusetts General Hospital, Harvard Medical School in Boston, Massachusetts.

Dr. Zhu received his doctorate (PhD) in the field of molecular biology at the State University of New York in Buffalo, N.Y. and Roswell Park Cancer Institute, and completed his post-doctoral training in brain tumor research at Children's Hospital, Brigham and Woman's Hospital, Harvard Medical School.


Prior to taking the position as the Director of Neuro-oncology service at UTHealth/Memorial Hermann at TMC in 2010, Dr. Zhu was an assistant professor and attending in neurology Tufts Medical Center and Tufts University School of Medicine in Boston, Massachusetts.

His many honors and awards include CUSBEA scholar (China and United States Biochemistry Exchange Application), Massachusetts Medical Society Scholarships, the Abby H. Shevitz, M.D. Young Physician award, and Teaching Award from the class of 2002 at Tufts University School of Medicine. Dr. Zhu was elected to the Fellow in American Academy of Neurology (FAAN) in 2019. He has been an active full member for three major academic societies: American Society of Clinical Oncology, American Academy of Neurology and Society of Neuro-oncology. He has over 70 peer reviewed publications in brain tumor research and has served as invited reviewers for many journals.



Onyee Chan, MD received her MD degree from the University of Arizona College of Medicine, Phoenix. She completed an Internal Medicine Residency at the University of Arizona College of Medicine in Tucson, followed by a Hematology/Oncology Fellowship at Moffitt Cancer Center/

University of South Florida. She is currently an assistant professor and clinical investigator at the Moffitt Cancer Center. Dr. Chan's clinical interests include myeloid malignancies, specifically acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Her research interests include clinical trials and outcome studies inspired by molecular targets that focus on myeloid neoplasms.



Jingsong Zhang, MD, PhD is a Genitourinary Oncologist and Interim Vice Chair, Department of Genitourinary Oncology at Moffitt Cancer Center, as well as an Associate Professor of Oncology and Internal Medicine at the University of South Florida College of Medicine. His primary research interest is in integrating tumor evolution dynamics into the treatment for advanced prostate cancer. As the clinical research director of Moffitt cancer center's genitourinary oncology program, he has been the principal Investigator (PI) and co-investigator of > 50 phase I, II and III clinical studies since joining Moffitt in July 2010. He is also the co-investigator on R21, R01, U01, U54 grants to study adaptive androgen deprivation therapy and immunotherapy in metastatic prostate cancer.



Fengting Yan, MD, PhD, is a medical oncologist at True Family Women's Cancer Center at the Swedish Cancer Institute in Seattle, Washington. She completed an internship and residency in Internal Medicine at The Ohio State University College of Medicine in Columbus and a fellowship in Hematology-Oncology at the Fred Hutchinson Cancer Research Center & University of Washington School of Medicine in Seattle. Dr. Yan is board-certified in Internal Medicine, Medical Oncology, and Hematology. Dr. Yan is the executive editor of the Journal of Women's Health Care, editorial board of the International Journal of Cancer Care and Delivery, chair of breast cancer committee of Binaytara foundation education academy, and her work has been published in such scholarly journals as JNCCN, The Journal of Nuclear Medicine, Blood, and Cancer Research. She is a member of the American Association for Cancer Research, and the American Society of Clinical Oncology. Dr. Yan currently serves as principal investigator for several phase 1 clinical research studies exploring new treatment options for breast cancer and ovarian cancer.



Eric Xueyu Chen, PhD, MD is a staff physician at the Department of Medical Oncology and Hematology, Princess Margaret Cancer Center, University Health Network, Toronto, Canada, and an associate professor of medical at Faculty of Medicine, University of Toronto. His clinical

activities focus on the treatment of gastrointestinal cancers. He participates in clinical trials evaluating new agents and treatment strategies for gastrointestinal cancers.



THE MOST THREATENING
EGFR MUTATION
MAY BE THE ONE
YOU DON'T SEE

Exon 20 insertion mutations in *EGFR*+ mNSCLC are more elusive and life-threatening than common *EGFR* mutations.¹⁻¹¹

These mutations differ from common mutations* in how they are detected and treated, leaving patients at risk of disease progression.¹⁻¹¹

Don't leave patients with mNSCLC at risk.

EXPLORE MORE AT [HIDDENEGFRTHREATS.COM](https://www.hiddenegfrthreats.com)

*Common mutations include L858R and exon 19 deletions.¹⁰

EGFR, epidermal growth factor receptor; mNSCLC, metastatic non-small cell lung cancer.

References: 1. Chiang AC, Fernandes AW, Pavlack M, et al. EGFR mutation testing and treatment decisions in patients progressing on first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors. *BMC Cancer*. 2020;20(1):356. 2. Robichaux JP, Elamin YY, Tan Z, et al. Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer. *Nat Med*. 2018;24(5):638-646. 3. Riess JW, Gandara DR, Frampton GM, et al. Diverse EGFR Exon 20 insertions and co-occurring molecular alterations identified by comprehensive genomic profiling of NSCLC. *J Thorac Oncol*. 2018;13(10):1560-1568. 4. Arcila ME, Nafa K, Chaff JE, et al. EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics. *Mol Cancer Ther*. 2013;12(2):220-229. 5. Oxnard GR, Lo PC, Nishino M, et al. Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions. *J Thorac Oncol*. 2013;8(2):179-184. 6. Naidoo J, Sima C, Rodriguez K, et al. Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: clinical outcomes and response to erlotinib. *Cancer*. 2015;121(18):3212-3220. 7. Chen D, Song Z, Cheng G. Clinical efficacy of first-generation EGFR-TKIs in patients with advanced non-small-cell lung cancer harboring EGFR exon 20 mutations. *Oncol Targets Ther*. 2016;9:4181-4186. 8. Bazhenova L, Minchom A, Viteri S, et al. Comparative clinical outcomes for patients with advanced NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutations. *Lung Cancer*. 2021;162:154-161. 9. Baum LJ, Viteri S, Minchom A, et al. Underdiagnosis of EGFR exon 20 insertion mutation variants: estimates from NGS-based real-world datasets. Presented at: the IASLC 2020 World Conference on Lung Cancer, January 28-31, 2021, Singapore. 10. Burnett H, Erlich H, Carroll C, Stapleton N, Mahadevia P, Li T. Epidemiological and clinical burden of EGFR exon 20 insertion in advanced non-small cell lung cancer: a systematic literature review. *PLoS One*. 2021;16(3):e0247620. 11. Lin J, Li M, Chen S, Weng L, He Z. Efficacy and safety of first-generation EGFR-TKIs combined with chemotherapy for treatment-naïve advanced non-small-cell lung cancer patients harboring sensitive EGFR mutations: a single-center, open-label, single-arm, phase II clinical trial. *J Inflamm Res*. 2021;14:2557-2567.

 **IMFINZI**[®]
durvalumab
Injection for Intravenous Use 50 mg/mL

 **IMJUDO**[®]
tremelimumab-actl
Injection for Intravenous Use 20 mg/mL

 **TAGRISSO**[®]
osimertinib

Visit the
AstraZeneca Booth
to learn more

AstraZeneca 

IMFINZI, IMJUDO, and TAGRISSO are registered trademarks of the AstraZeneca group of companies.
©2023 AstraZeneca. All rights reserved. US-74239 3/23

NOW APPROVED IN A 4TH INDICATION

**EVEN MORE
PATIENTS
MAY BE RIGHT
FOR BRUKINSA**



**REVIEW THE TRIALS SUPPORTING
THE LATEST APPROVAL**

BeiGene and BRUKINSA are registered trademarks
owned by BeiGene, Ltd. or its affiliates.
© BeiGene, Ltd. 2023 All Rights Reserved.
0522-BRU-PRC-038 1/2023





Chinese American Hematologist and Oncologist Network (CAHON)
555 East Wells Street, Suite 1100 • Milwaukee, WI 53202 USA
Phone: 1 414-918-9890 • Fax: 1 414-276-3349